NEW YORK, March 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that Ron Bentsur, the Company’s Chief Executive Officer, is scheduled to present tomorrow at Oppenheimer’s “Positioning Investors for the Next Wave in Pain Management” Conference. Mr. Bentsur will present an overview of Bicifadine, the Company’s recently in-licensed late-stage clinical compound for the treatment of neuropathic pain, in a presentation titled: “Bicifadine - A New Idea for Neuropathic Pain.” Mr. Bentsur’s presentation will take place on Tuesday, March 6, 2007, at 2:25pm-2:40pm Eastern Standard Time followed by a question and answer session from 2:55pm-3:15pm., at the Flatotel Hotel in New York City.
A live audio webcast of Mr. Bentsur’s presentation will be available at: http://www.wsw.com/webcast/opp/xtl.l/. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. (“XTL”) is engaged in the acquisition, development and commercialization of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL’s hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges .
Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960
XTL Biopharmaceuticals Ltd
CONTACT: Contact: Ron Bentsur, Chief Executive Officer, Tel:+1-(212)-531-5960
